Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 49, 2008, Pages 19532-19537

  Zhang, Lingzhi ^a   Murray, Fiona ^a   Zahno, Anja ^a   Kanter, Joan R ^a   Chou, Daisy ^a   Suda, Ryan ^a   Fenlon, Michael ^b,c   Rassenti, Laura ^b,c   Cottam, Howard ^b,c   Kipps, Thomas J ^b,c   Insel, Paul A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Apoptosis; B cell; cAMP; Survivin

Indexed keywords

2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENZYME INHIBITOR; IR 202; IR 284; MESSENGER RNA; PHOSPHODIESTERASE 7B; PHOSPHODIESTERASE VII; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA FINGERPRINTING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; APOPTOSIS; B-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; PHOSPHODIESTERASE INHIBITORS; RNA, MESSENGER;

EID: 58049194092     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0806152105     Document Type: Article

References (47)

1. Danilov AV, Danilova OV, Klein AK, Huber BT (2006) Molecular pathogenesis of chronic lymphocytic leukemia. Curr Mol Med 6(6):665-675.
2. Zhang L, Insel PA (2004) The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells. J Biol Chem 279(20):20858-20865.
3. Tiwari S, et al. (2005) Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 69(3):473-483.
4. Kim DH, Lerner A (1998) Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92(7):2484-2494.
5. Monahan TM, Marchand NW, Fritz RR, Abell CW (1975) Cyclic adenosine 3′:5′-monophosphate levels and activities of related enzymes in normal and leukemic lymphocytes. Cancer Res 35(9):2540-2547.
6. Carpentieri U, Monahan TM, Gustavson LP (1980) Observations on the level of cyclic nucleotides in three population of human lymphocytes in culture. J Cyclic Nucleotide Res 6(4):253-259.
7. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58(3):488-520.
8. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
9. Mentz F, Merle-Beral H, Dalloul AH (1999) Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production. Leukemia 13(1):78-84.
10. Mentz F, et al. (1996) Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 88(6):2172-2182.
11. Mabed M, Aref S, Fouda M, El-Sharawy S (2004) Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia. Leuk Lymphoma 45(10):2029-2035.
12. Willis CR, et al. (2006) A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Ann Hematol 85(5):301-307.
13. Moon E, et al. (2002) Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin Cancer Res 8(2):589-595.
14. Lerner A, Epstein PM (2006) Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393(1):21-41.
15. Lee R, et al. (2002) PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signalling 14(3):277-284.
16. Smith SJ, et al. (2004) Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66(6):1679-1689.
17. Vergne F, et al. (2004) Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivatives. Bioorg Med Chem Lett 14(18):4615-4621.
18. Nakata A, et al. (2002) Potential role of phosphodiesterase 7 in human T cell function: Comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 128(3):460-466.
19. Moon EY, Lerner A (2003) PDE4 inhibitors activate amitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 101(10):4122-4130.
20. Smal C, et al. (2007) Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2′-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB. Biochem Pharmacol 73(3):351-358.
21. Tiwari S, et al. (2004) Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood 103(7):2661-2667.
22. Martinez-Caballero S, Dejean LM, Jonas EA, Kinnally KW (2005) The role of the mitochondrial apoptosis induced channel MAC in cytochrome c release. J Bionenerg Biomembr 37(3):155-164.
23. Zhang L, et al. (2008) Gene expression signatures of cAMP/protein kinase A (PKA)-promoted, mitochondrial-dependent apoptosis. Comparative analysis of wild-type and cAMP-deathless S49 lymphoma cells. J Biol Chem 283(7):4304-4313.
24. Persani L, et al. (2001) Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: Effect of Gs(alpha) mutations. J Clin Endocrinol Metab 86(8):3795-3800.
25. Fryknas M, et al. (2006) Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model. J Biomol Screen 11(5):457-468.
26. Ekholm D, et al. (1999) Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes. Biochem Pharmacol 58(6):935-950.
27. Jiang X, Li J, Paskind M, Epstein PM (1996) Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci USA 93(20):11236-11241.
28. Murray F, et al. (2007) Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: Role for PDE1. Am J Physiol 292(1):L294-L303.
29. Bloom TJ, Beavo JA (1996) Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 93(24):14188-14192.
30. Michaeli T, et al. (1993) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 268(17):12925-12932.
31. Hetman JM, Soderling SH, Glavas NA, Beavo JA (2000) Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 97(1):472-476.
32. Sasaki T, Kotera J, Yuasa K, Omori K (2000) Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 271(3):575-583.
33. Gantner F, et al. (1998) Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123(6):1031-1038.
34. Smith SJ, et al. (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol 284(2):L279-L289.
35. Giembycz MA, Smith SJ (2006) Phosphodiesterase 7A: A new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 12(25):3207-3220.
36. Li L, Yee C, Beavo JA (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283(5403):848-851.
37. Sasaki T, Kotera J, Omori K (2004) Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 89(2):474-483.
38. HanP, Sonati P, Rubin C, Michaeli T (2006) PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem 281(22):15050-15057.
39. Pekkinen M, Ahlstrom ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ (2008) Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. Bone 43(1):84-91.
40. Giembycz MA (2001) Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10(7):1361-1379.
41. Dodge-Kafka KL, et al. (2005) The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437(7058):574-578.
42. Granziero L, et al. (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97(9):2777-2783.
43. Decker T, et al. (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101(1):278-285.
44. McCahill A, et al. (2008) In cardiac myocytes, cAMP elevation triggers the downregulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). Cell Signalling 20(11):2071-2083.
45. Ding B, et al. (2005) A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 102(41):14771-14776.
46. Rassenti LZ, et al. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351(9):893-901.
47. Thompson WJ, Appleman MM (1971) Cyclic nucleotide phosphodiesterase and cyclic AMP. Ann NY Acad Sci 185:36-41.